Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
Tag: visualeditor |
m Tag: visualeditor |
||
| Line 1: | Line 1: | ||
| − | == Metastatic disease == | + | ==Metastatic disease== |
| − | === Selpercatinib monotherpay === | + | ===Selpercatinib monotherpay=== |
| − | + | '''Regimen''' | |
| − | |||
{| class="wikitable" | {| class="wikitable" | ||
!FDA-recommended dose | !FDA-recommended dose | ||
| Line 18: | Line 17: | ||
|Phase I/II | |Phase I/II | ||
|} | |} | ||
| + | '''Biomarker eligibility criteria''' | ||
| − | + | *Biomarker: RET fusion positive | |
| − | |||
| − | * Biomarker: RET fusion positive | ||
| − | + | '''Chemotherapy''' | |
| − | * Selpercatinib 120 mg (<50 kg) and 160 mg (<u>></u>50 kg) orally twice daily | + | *Selpercatinib 120 mg (<50 kg) and 160 mg (<u>></u>50 kg) orally twice daily |
| − | + | '''Continued indefinitely''' | |
| − | + | '''References''' | |
| − | # '''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract.] | + | #'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract.] |
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Lung cancers]] | [[Category:Lung cancers]] | ||
| + | <references /> | ||
Revision as of 03:28, 14 July 2020
Metastatic disease
Selpercatinib monotherpay
Regimen
| FDA-recommended dose |
|---|
| Study | Years of enrollment | Evidence |
|---|---|---|
| Drilon et al. 2019
LIBRETTO-001[1] |
Phase I/II |
Biomarker eligibility criteria
- Biomarker: RET fusion positive
Chemotherapy
- Selpercatinib 120 mg (<50 kg) and 160 mg (>50 kg) orally twice daily
Continued indefinitely
References
- Abstract. Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. link to abstract.
- ↑ https://www.jto.org/article/S1556-0864(19)30742-7/abstract